



**DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors**

Dottikon, Switzerland, August 18, 2006 – At the 1st Annual General Meeting of DOTTIKON ES HOLDING AG for the business year 2005/06 carried out in the Technopark in Zurich, the shareholders approved all proposals of the Board of Directors. 212 present shareholders represented 1'029'354 voting rights and therefore 83.5% of the total of 1'233'107 registered shares in circulation.

The annual report, financial statements 2005/06 and the consolidated financial report of the DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Further the dividend payment of CHF 8.00 per share entitled to dividends was accepted with great majority. Discharge for the business year 2005/06 was granted to the responsible Board of Directors and Management. All members of the Board, Heinz Boller, Dr. h.c. Grogg and Dr. Robert Hofer, are re-elected for an additional term of one year. Group auditors and statutory auditors for the present term is KPMG Fides Peat, Zurich.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), specializes on hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

For further information please contact

Rémy Scheidegger  
Senior Assistant to CEO

DOTTIKON ES HOLDING AG  
Tel +41 56 616 82 01  
Fax +41 56 616 89 45  
[remy.scheidegger@dottikon.com](mailto:remy.scheidegger@dottikon.com)